

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

## **M.8397 - PARTNERS GROUP / CERBA HEALTHCARE**

### **SECTION 1.2**

#### **Description of the concentration**

On 7 March 2017, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004, by which certain investment funds advised and/or managed by Partners Group AG or its affiliates (“**Partners Group**”) will acquire sole control of Cerba Healthcare (the “**Target**”). The acquisition will be implemented by way of a share purchase of 100% of the issued share capital of Financière Gaillon 0 (the holding company of the Target) by a number of newly formed special purpose vehicles controlled by Partners Group.

Partners Group AG is a stock corporation incorporated in Switzerland with its registered office and headquarters at Zugerstrasse 57, 6341 Baar-Zug, Switzerland. The Target is headquartered in France.

The business activities of the undertakings concerned are as follows:

- i) Partners Group: private markets investment management company.
- ii) Target: provision of laboratory services in the clinical pathology markets.

The Target is active in the market for biomedical laboratory analysis.